NCT05717803RecruitingPhase 3
Segmentectomy for Ground Glass-dominant Invasive Lung Cancer (ECTOP-1012)
Segmentectomy for Ground Glass-dominant Invasive Lung Cancer With Size of 2-3cm: a Single-arm, Multi-center, Phase III Trial
Source: ClinicalTrials.gov · Last updated 3 Jun 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This is a clinical trial from Eastern Cooperative Thoracic Oncology Project (ECTOP), numbered as ECTOP-1012. The goal of this clinical trial is to confirm the theraputic effect of segmentectomy for ground glass-dominant invasive lung cancer with size of 2-3cm. The main questions it aims to answer are: * The 5-year disease-free survival of patients having ground glass-dominant invasive lung cancer with size of 2-3cm; * The post-operative lung function tests after receiving segmentectomy. Participants will receive segmentectomy as the surgical procedure.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 307 (estimated)
- First submitted
- 6 Jan 2023
- Start date
- 15 Feb 2023
- Primary completion date
- 31 Dec 2028
- Lead sponsor
- Fudan University
- Diseases
- Lung cancer
- NCT number
- NCT05717803
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 307
- From 15 Feb 2023 to the primary completion date, 31 Dec 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Receiving lung cancer surgery before;
- Receiving radiotherapy or chemotherapy.
Other
- CTR is not 0-0.5, or size is not 2-3cm;
- Tumors could not be completely resected assed by surgeons;
- Not lung adenocarcinoma diagnosed cytologically or pathologically;
Who the study is looking for
- Patients who sign the informed consent form and are willing to complete the study according to the plan;
- Aged from 18 to 80 years old;
- ECOG equals 0 or 1;
- Not receiving lung cancer surgery before;
- Confirmed to be invasive lung adenocarcinoma intraoperatively or postoperatively;
- Ground glass-dominant lung nodules
- Consolidation-to-tumor ratio (CTR) ranges from 0 to 0.5, and tumor size ranges from 2 to 3cm;
- cN0 without distant metastasis;
- Tumors could be completely resected assed by surgeons;
- Not receiving chemotherapy or radiotherapy before.
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Fudan University Shanghai Cancer Center Coordinator of this site? Confirm its status | Shanghai | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.